Keros Therapeutics Approves Up to $5 Million Share Buyback
Keros said the board approved the buyback after the company received a $20 million development milestone payment under its license agreement with Takeda Pharmaceuticals for elritercept.
Keros said the board approved the buyback after the company received a $20 million development milestone payment under its license agreement with Takeda Pharmaceuticals for elritercept.